Riskpilot← Back to searchSign inGet full accessBonipharmex AB
ABActiveOrg 5590316062Gustav Iii:S Boulevard 10Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20151 employees
Revenue 2024
SEK 6M
+103% vs 2023
EBITDA margin
-30.4%
+6% vs 2023
Equity ratio
1.4%
Financial strength
Net profit 2024
SEK 8K
-71% vs 2023
| Revenue | SEK 6M | +103% |
| EBITDA | SEK -1,8M | +6% |
| Net profit | SEK 8K | -71% |
| Total assets | SEK 7,1M | +77% |
| Equity | SEK 100K | +77% |
| Employees | 1 | — |
Legal name
Bonipharmex AB
Org number
5590316062
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22 oktober 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget bedriver marknadsföring och försäljning av medicintekniska produkter, kosmetiska produkter och kosttillskott samt därmed förenlig verksamhet.
Address
Gustav Iii:S Boulevard 10
Email
hamid.bakhshi@startuppharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 331 | 65 | 101 | 960 | 2 352 | 2 976 | 6 036 |
| Staff expenses | — | — | — | — | — | — | −16 | −12 | −17 |
| EBITDA | 268 | 212 | 99 | 138 | 39 | 3 | −1 371 | −1 962 | −1 835 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — |
| EBIT | 268 | 212 | 99 | 138 | 39 | 3 | −1 371 | −1 962 | −1 835 |
| Net financials | — | — | −2 | −21 | −32 | — | 0 | 0 | 0 |
| Profit before tax | 268 | 212 | 98 | 117 | 6 | 3 | −28 | 38 | 15 |
| Tax | −60 | −47 | −22 | −26 | −1 | −2 | — | −10 | −7 |
| Net profit | 208 | 165 | 76 | 91 | 5 | 1 | −28 | 28 | 8 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 548 | 629 | 1 537 | 1 527 | 332 | 1 002 | 1 739 | 4 031 | 7 143 |
| Equity | 258 | 301 | 126 | 177 | 55 | 57 | 29 | 56 | 100 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Short-term debt | 290 | 328 | 1 411 | 1 350 | 276 | 945 | 1 711 | 3 975 | 7 043 |
| Total debt | 290 | 328 | 1 411 | 1 350 | 276 | 945 | 1 711 | 3 975 | 7 043 |
EBITDA margin
-30.4%
This company
15.8%
Market median
-292% vs market
20162024
Equity ratio
1.4%
This company
38.2%
Market median
-96% vs market
20162024
Return on equity
8.0%
This company
18.4%
Market median
-57% vs market
20162024
Net profit margin
0.1%
This company
8.1%
Market median
-99% vs market
20162024
Asset turnover
0.85×
This company
1.12×
Market median
+24% vs market
20162024
Debt / equity
70.67×
This company
0.62×
Market median
-11298% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-11-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-11-01 – 2019-10-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-11-01 – 2018-10-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-11-01 – 2017-10-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-10-01 – 2016-10-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ER Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
BS Audit | Audit | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Barnik Invest AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bonipharmex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elham Rezaei | Chief Executive Officer | 0 companies |
| Bo Sonny Malmquist | Audit | 0 companies |
| Carl Anders Tage Persson | Deputy Board Member | 0 companies |
| Hamid Baradaran Bakhshi | Chairman | 0 companies |
| Sara Nikman | Board of Directors | 0 companies |